Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 gene
| Autor: | Richard E. Lutz, Priya S. Kishnani, Avihu Boneh, Deeksha Bali, Stephanie Austin, Keri Fredrickson, Anne Boney, Catherine Rehder, Jennifer L. Goldstein, David A. Weinstein |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Glycogen Storage Disease Type IX
Male medicine.medical_specialty Cirrhosis Adolescent Phosphorylase Kinase Endocrinology Diabetes and Metabolism Hypoglycemia Biology medicine.disease_cause Biochemistry Gastroenterology Article Endocrinology Internal medicine Genetics medicine Glycogen storage disease Humans Phosphorylase kinase Child Molecular Biology Mutation medicine.diagnostic_test Infant medicine.disease Glycogen Storage Disease Ketotic hypoglycemia Liver Liver biopsy Child Preschool Female Hepatomegaly |
| Zdroj: | Molecular genetics and metabolism. 111(3) |
| ISSN: | 1096-7206 |
| Popis: | Liver phosphorylase b kinase (PhK) deficiency (glycogen storage disease type IX), one of the most common causes of glycogen storage disease, is caused by mutations in the PHKA2, PHKB, and PHKG2 genes. Presenting symptoms include hepatomegaly, ketotic hypoglycemia, and growth delay. Clinical severity varies widely. Autosomal recessive mutations in the PHKG2 gene, which cause about 10-15% of cases, have been associated with severe symptoms including increased risk of liver cirrhosis in childhood. We have summarized the molecular, biochemical, and clinical findings in five patients, age 5-16 years, diagnosed with liver PhK deficiency caused by PHKG2 gene mutations. We have identified five novel and two previously reported mutations in the PHKG2 gene in these five patients. Clinical severity was variable among these patients. Histopathological studies were performed for four of the patients on liver biopsy samples, all of which showed signs of fibrosis but not cirrhosis. One of the patients (aged 9 years) developed a liver adenoma which later resolved. All patients are currently doing well. Their clinical symptoms have improved with age and treatment. These cases add to the current knowledge of clinical variability in patients with PHKG2 mutations. Long term studies, involving follow-up of these patients into adulthood, are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect